

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Memorial Sloan Kettering Cancer Center
Enrollment	37 participants

Key Eligibility Criteria

Inclusion (18)

- Patients with a diagnosis of primary myelofibrosis, post-ET myelofibrosis, post-PV myelofibrosis, or post-pre-fibrotic myelofibrosis by WHO 2016 criteria.
- Age ≥18 years.
- Receiving ruxolitinib monotherapy for at least 3 months with stable dose (10 mg BID to 20mg BID) for at least 4 weeks before first dose of study drug. Note: stable ruxolitinib dosing should be achieved according to strict adherence to dose modification/reduction guidelines detailed in the ruxolitinib package insert, for patients with renal impairment, and/or hepatic impairment.
- Must have DIPSS+ intermediate 2 or greater risk disease, or MIPSS70+ intermediate or greater risk disease
- Persistent disease despite ruxolitinib monotherapy, as demonstrated by:
... and 13 more (see full listing online)

Exclusion (25)

- Use of experimental drug therapy for MF or any other standard drug with the exception of hydroxyurea or ruxolitinib within 2 weeks of starting combination therapy and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better. Hydroxyurea may be utilized to control leukocytosis for up to 4 weeks during study
- Participants with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Unwilling to receive red blood cell transfusion to treat low hemoglobin.
- Participants who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib and ulixertinib.
... and 20 more (see full listing online)

Locations (9 total)

Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
... and 6 more locations

<https://clinicaltrials.gov/study/NCT06773195>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).